The flavivirus protease as a target for drug discovery

Virologica Sinica

Volumn 28, Issue 6, 2013, Pages 326-336

  Brecher, Matthew ^a   Zhang, Jing ^a   Li, Hongmin ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Flavivirus; Inhibitor; Protease

Indexed keywords

NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; POLYPROTEIN; PROTEINASE; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DRUG DEVELOPMENT; FLAVIVIRUS; LIFE CYCLE; NONHUMAN; REVIEW; VIRUS GENOME; VIRUS REPLICATION;

FLAVIVIRUS;

ANTIVIRAL AGENTS; DRUG DISCOVERY; FLAVIVIRUS; HUMANS; PROTEASE INHIBITORS; RNA HELICASES; SERINE ENDOPEPTIDASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84891560753     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-013-3390-x     Document Type: Review

References (132)

1. Ackermann M, and Padmanabhan R. 2001. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem, 276: 39926-39937.
2. Aleshin A, Shiryaev S, Strongin A, and Liddington R. 2007. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci., 16: 795-806.
3. Aravapalli S, Lai H, Teramoto T, Alliston K R, Lushington G H, Ferguson E L, Padmanabhan R, and Groutas W C. 2012. Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold. Bioorg Med Chem, 20: 4140-4148.
4. Arias C F, Preugschat F, and Strauss J H. 1993. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology, 193: 888-899.
5. Ashour J, Laurent-Rolle M, Shi P Y, and Garcia-Sastre A. 2009. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol, 83: 5408-5418.
6. Asnis D S, Conetta R, Waldman G, and Teixeira A A. 2001. The West Nile virus encephalitis outbreak in the United States (1999-2000): from Flushing, New York, to beyond its borders. Ann N Y Acad Sci, 951: 161-171.
7. Asnis D S, Conetta R, Teixeira A A, Waldman G, and Sampson B A. 2000. The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis, 30: 413-418.
8. Assenberg R, Mastrangelo E, Walter T S, Verma A, Milani M, Owens R J, Stuart D I, Grimes J M, and Mancini E J. 2009. Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. J Virol, 83: 12895-12906.
9. Bazan J F, and Fletterick R J. 1989. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology, 171: 637-639.
10. Best S M, Morris K L, Shannon J G, Robertson S J, Mitzel D N, Park G S, Boer E, Wolfinbarger J B, and Bloom M E. 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol., 79: 12828-12839.
11. Bodenreider C, Beer D, Keller T H, Sonntag S, Wen D, Yap L, Yau Y H, Shochat S G, Huang D, Zhou T, Caflisch A, Su X C, Ozawa K, Otting G, Vasudevan S G, Lescar J, and Lim S P. 2009. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem, 395: 195-204.
12. Bressanelli S, Stiasny K, Allison S L, Stura E A, Duquerroy S, Lescar J, Heinz F X, and Rey F A. 2004. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J., 23: 728-738.
13. Brinton M A. 1981. Isolation of a replication-efficient mutant of West Nile virus from a persistently infected genetically resistant mouse cell culture. J Virol, 39: 413-421.
14. Brinton M A. 2002. THE MOLECULAR BIOLOGY OF WEST NILE VIRUS: A New Invader of the Western Hemisphere. Annu Rev Microbiol, 56: 371-402.
15. Burke D S, and Monath T P. 2001. Flaviviruses. Lippincott William & Wilkins.
16. CDC. 2010. CDC West Nile virus homepage. http://www.cdc.gov/ncidod/dvbid/ westnile/surv&controlCaseCount03.htm.
17. Chambers T J, Grakoui A, and Rice C M. 1991. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J. Virol., 65: 6042-6050.
18. Chambers T J, Hahn C S, Galler R, and Rice C M. 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol, 44: 649-688.
19. Chambers T J, Nestorowicz A, Amberg S M, and Rice C M. 1993. Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol, 67: 6797-6807.
20. Chambers T J, Droll D A, Tang Y, Liang Y, Ganesh V K, Murthy K H, and Nickells M. 2005. Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities. J Gen Virol, 86: 1403-1413.
21. Chandramouli S, Joseph J S, Daudenarde S, Gatchalian J, Cornillez-Ty C, and Kuhn P. 2010. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol, 84: 3059-3067.
22. Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, and Katzenmeier G. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun, 330: 1237-1246.
23. Chappell K J, Stoermer M J, Fairlie D P, and Young P R. 2006. Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem, 281: 38448-38458.
24. Chappell K J, Stoermer M J, Fairlie D P, and Young P R. 2008. West Nile Virus NS2B/NS3 protease as an antiviral target. Curr Med Chem, 15: 2771-2784.
25. Chappell K J, Stoermer M J, Fairlie D P, and Young P R. 2008. Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity. J Gen Virol, 89: 1010-1014.
26. Cleaves G R, and Dubin D T. 1979. Methylation status of intracellular dengue type 2 40 S RNA. Virology, 96: 159-165.
27. Cregar-Hernandez L, Jiao G S, Johnson A T, Lehrer A T, Wong T A, and Margosiak S A. 2011. Small molecule pan-dengue and West Nile virus NS3 protease inhibitors. Antivir Chem Chemother, 21: 209-217.
28. Daffis S, Szretter K J, Schriewer J, Li J, Youn S, Errett J, Lin T Y, Schneller S, Zust R, Dong H, Thiel V, Sen G C, Fensterl V, Klimstra W B, Pierson T C, Buller R M, Gale M, Jr., Shi P Y, and Diamond M S. 2010. 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature, 468: 452-456.
29. Deng J, Li N, Liu H, Zuo Z, Liew O W, Xu W, Chen G, Tong X, Tang W, Zhu J, Zuo J, Jiang H, Yang C G, Li J, and Zhu W. 2012. Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. J Med Chem, 55: 6278-6293.
30. Dong H, Chang D C, Hua M H, Lim S P, Chionh Y H, Hia F, Lee Y H, Kukkaro P, Lok S M, Dedon P C, and Shi P Y. 2012. 2′-O methylation of internal adenosine by flavivirus NS5 methyltransferase. PLoS pathogens, 8: e1002642.
31. Egloff M P, Benarroch D, Selisko B, Romette J L, and Canard B. 2002. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. Embo J, 21: 2757-2768.
32. Ekonomiuk D, Su X C, Ozawa K, Bodenreider C, Lim S P, Otting G, Huang D, and Caflisch A. 2009. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. J Med Chem, 52: 4860-4868.
33. Ekonomiuk D, Su X C, Ozawa K, Bodenreider C, Lim S P, Yin Z, Keller T H, Beer D, Patel V, Otting G, Caflisch A, and Huang D. 2009. Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. PLoS Negl Trop Dis, 3: e356.
34. Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim S, Yin Z, Keller T, Vasudevan S, and Hommel U. 2006. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol., 13: 372-373.
35. Ezgimen M, Lai H, Mueller N H, Lee K, Cuny G, Ostrov D A, and Padmanabhan R. 2012. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antiviral Res, 94: 18-24.
36. Falgout B, Miller R H, and Lai C J. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J Virol, 67: 2034-2042.
37. Falgout B, Bray M, Schlesinger J J, and Lai C J. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol, 64: 4356-4363.
38. Falgout B, Pethel M, Zhang Y M, and Lai C J. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol, 65: 2467-2475.
39. Ganesh V K, Muller N, Judge K, Luan C H, Padmanabhan R, and Murthy K H. 2005. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem, 13: 257-264.
40. Gao Y, Cui T, and Lam Y. 2010. Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease. Bioorg Med Chem, 18: 1331-1336.
41. Gao Y, Samanta S, Cui T, and Lam Y. 2013. Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 1,3,4,5-Tetrasubstituted 1H-Pyrrol-2(5H)-one Scaffold. ChemMedChem, 8: 1554-1560.
42. Gouvea I E, Izidoro M A, Judice W A, Cezari M H, Caliendo G, Santagada V, dos Santos C N, Queiroz M H, Juliano M A, Young P R, Fairlie D P, and Juliano L. 2007. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates. Arch Biochem Biophys, 457: 187-196.
43. Grant D, Tan G K, Qing M, Ng J K, Yip A, Zou G, Xie X, Yuan Z, Schreiber M J, Schul W, Shi P Y, and Alonso S. 2011. A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis. J Virol, 85: 7775-7787.
44. Guirakhoo F, Bolin R A, and Roehrig J T. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology, 191: 921-931.
45. Guo J, Hayashi J, and Seeger C. 2005. West nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol., 79: 1343-1350.
46. Guyatt K J, Westaway E G, and Khromykh A A. 2001. Expression and purification of enzymatically active recombinant RNA-dependent RNA polymerase (NS5) of the flavivirus Kunjin. J Virol Methods, 92: 37-44.
47. Hammamy M Z, Haase C, Hammami M, Hilgenfeld R, and Steinmetzer T. 2013. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem, 8: 231-241.
48. Issur M, Geiss B J, Bougie I, Picard-Jean F, Despins S, Mayette J, Hobdey S E, and Bisaillon M. 2009. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. Rna, 15: 2340-2350.
49. Jia F, Zou G, Fan J, and Yuan Z. 2010. Identification of palmatine as an inhibitor of West Nile virus. Arch Virol, 155: 1325-1329.
50. Johnston P A, Phillips J, Shun T Y, Shinde S, Lazo J S, Huryn D M, Myers M C, Ratnikov B I, Smith J W, Su Y, Dahl R, Cosford N D, Shiryaev S A, and Strongin A Y. 2007. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol, 5: 737-750.
51. Kiat T S, Pippen R, Yusof R, Ibrahim H, Khalid N, and Rahman N A. 2006. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett, 16: 3337-3340.
52. Knehans T, Schuller A, Doan D N, Nacro K, Hill J, Guntert P, Madhusudhan M S, Weil T, and Vasudevan S G. 2011. Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J Comput Aided Mol Des, 25: 263-274.
53. Knox J E, Ma N L, Yin Z, Patel S J, Wang W L, Chan W L, Ranga Rao K R, Wang G, Ngew X, Patel V, Beer D, Lim S P, Vasudevan S G, and Keller T H. 2006. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J Med Chem, 49: 6585-6590.
54. Koonin E V. 1993. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol, 74: 733-740.
55. Kramer L D, and Bernard K A. 2001. West Nile virus infection in birds and mammals. Ann N Y Acad Sci, 951: 84-93.
56. Kramer L D, Li J, and Shi P Y. 2007. West Nile virus. Lancet Neurol, 6: 171-181.
57. Kummerer B M, and Rice C M. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol., 76: 4773-4784.
58. Lai H, Sridhar Prasad G, and Padmanabhan R. 2013. Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Antiviral Res, 97: 74-80.
59. Lai H, Dou D, Aravapalli S, Teramoto T, Lushington G H, Mwania T M, Alliston K R, Eichhorn D M, Padmanabhan R, and Groutas W C. 2013. Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Bioorg Med Chem, 21: 102-113.
60. Leung D, Schroder K, White H, Fang N-X, Stoermer M, Abbenante G, Martin J, PR Y, and Fairlie D. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem., 276: 45762-45771.
61. Leung J Y, Pijlman G P, Kondratieva N, Hyde J, Mackenzie J M, and Khromykh A A. 2008. Role of nonstructural protein NS2A in flavivirus assembly. J Virol, 82: 4731-4741.
62. Li H, Clum S, You S, Ebner K E, and Padmanabhan R. 1999. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol, 73: 3108-3116.
63. Li J, Lim S P, Beer D, Patel V, Wen D, Tumanut C, Tully D C, Williams J A, Jiricek J, Priestle J P, Harris J L, and Vasudevan S G. 2005. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem, 280: 28766-28774.
64. Li L, Lok S M, Yu I M, Zhang Y, Kuhn R J, Chen J, and Rossmann M G. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science, 319: 1830-1834.
65. Lin C, Kwong A D, and Perni R B. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets, 6: 3-16.
66. Lin K, Perni R B, Kwong A D, and Lin C. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother, 50: 1813-1822.
67. Lindenbach B D, and Rice C M. 1997. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol., 71: 9608-9617.
68. Lindenbach B D, and Rice C M. 1999. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol, 73: 4611-4621.
69. Lindenbach B D, Thiel H J, and Rice C M. 2007. Flaviviridae: The Virus and Their Replication, Fourth ed. Lippincott William & Wilkins.
70. Luo D, Xu T, Hunke C, Gruber G, Vasudevan S G, and Lescar J. 2008. Crystal structure of the NS3 protease-helicase from dengue virus. J Virol, 82: 173-183.
71. Luo D, Wei N, Doan D N, Paradkar P N, Chong Y, Davidson A D, Kotaka M, Lescar J, and Vasudevan S G. 2010. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem, 285: 18817-18827.
72. Luo D, Xu T, Watson R P, Scherer-Becker D, Sampath A, Jahnke W, Yeong S S, Wang C H, Lim S P, Strongin A, Vasudevan S G, and Lescar J. 2008. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. Embo J, 27: 3209-3219.
73. Mangano D T, Tudor I C, and Dietzel C. 2006. The risk associated with aprotinin in cardiac surgery. N Engl J Med, 354: 353-365.
74. Mangano D T, Miao Y, Vuylsteke A, Tudor I C, Juneja R, Filipescu D, Hoeft A, Fontes M L, Hillel Z, Ott E, Titov T, Dietzel C, and Levin J. 2007. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA, 297: 471-479.
75. Marianneau P, Steffan A M, Royer C, Drouet M T, Jaeck D, Kirn A, and Deubel V. 1999. Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol, 73: 5201-5206.
76. Menendez-Arias L. 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res, 85: 210-231.
77. Miller S, Kastner S, Krijnse-Locker J, Buhler S, and Bartenschlager R. 2007. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J Biol Chem, 282: 8873-8882.
78. Modis Y, Ogata S, Clements D, and Harrison S C. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature, 427: 313-319.
79. Mueller N H, Yon C, Ganesh V K, and Padmanabhan R. 2007. Characterization of the West Nile virus protease substrate specificity and inhibitors. Int J Biochem Cell Biol, 39: 606-614.
80. Mueller N H, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson T C, and Padmanabhan R. 2008. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother, 52: 3385-3393.
81. Munoz-Jordan J L, Sanchez-Burgos G G, Laurent-Rolle M, and Garcia-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA, 100: 14333-14338.
82. Munoz-Jordan J L, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin W I, and Garcia-Sastre A. 2005. Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses. J. Virol., 79: 8004-8013.
83. Muylaert I R, Galler R, and Rice C M. 1997. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J. Virol., 71: 291-298.
84. Nall T A, Chappell K J, Stoermer M J, Fang N X, Tyndall J D, Young P R, and Fairlie D P. 2004. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem, 279: 48535-48542.
85. Nitsche C, Steuer C, and Klein C D. 2011. Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. Bioorg Med Chem, 19: 7318-7337.
86. Nitsche C, Behnam M A, Steuer C, and Klein C D. 2012. Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Res, 94: 72-79.
87. Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S, and Katzenmeier G. 2004. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J Virol, 78: 13708-13716.
88. Noble C G, Seh C C, Chao A T, and Shi P Y. 2012. Ligand-bound structures of the dengue virus protease reveal the active conformation. Journal of Virology, 86: 438-446.
89. Noble C G, Chen Y L, Dong H, Gu F, Lim S P, Schul W, Wang Q Y, and Shi P Y. 2010. Strategies for development of Dengue virus inhibitors. Antiviral Res, 85: 450-462.
90. Pambudi S, Kawashita N, Phanthanawiboon S, Omokoko M D, Masrinoul P, Yamashita A, Limkittikul K, Yasunaga T, Takagi T, Ikuta K, and Kurosu T. 2013. A Small Compound Targeting the Interaction between Nonstructural Proteins 2B and 3 Inhibits Dengue Virus Replication. Biochem Biophys Res Commun: in press (doi: 10.1016/j.bbrc.2013.1009.1078).
91. Phong W Y, Moreland N J, Lim S P, Wen D, Paradkar P N, and Vasudevan S G. 2011. Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target. Bioscience reports.
92. Radichev I, Shiryaev S A, Aleshin A E, Ratnikov B I, Smith J W, Liddington R C, and Strongin A Y. 2008. Structure-based mutagenesis identifies important novel determinants of the NS2B cofactor of the West Nile virus two-component NS2B-NS3 proteinase. J Gen Virol, 89: 636-641.
93. Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, Dong H, Deas T, Zhou Y, Li H, and Shi P. 2006. West nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J. Virol., 80: 8362-8370.
94. Rice C M, Lenches E M, Eddy S R, Shin S J, Sheets R L, and Strauss J H. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science, 229: 726-733.
95. Robin G, Chappell K, Stoermer M J, Hu S H, Young P R, Fairlie D P, and Martin J L. 2009. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol, 385: 1568-1577.
96. Romano K P, Ali A, Royer W E, and Schiffer C A. 2010. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A, 107: 20986-20991.
97. Roosendaal J, Westaway E G, Khromykh A, and Mackenzie J M. 2006. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J Virol, 80: 4623-4632.
98. Rothan H A, Han H C, Ramasamy T S, Othman S, Rahman N A, and Yusof R. 2012. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis, 12: 314.
99. Samanta S, Cui T, and Lam Y. 2012. Discovery, synthesis, and in vitro evaluation of West Nile virus protease inhibitors based on the 9,10-dihydro-3H,4aH-1,3,9,10a-tetraazaphenanthren-4-one scaffold. ChemMedChem, 7: 1210-1216.
100. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta S K, Hussain M, Shah A, Cutler D, Zhang J, and Zeuzem S. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 132: 1270-1278.
101. Schuller A, Yin Z, Brian Chia C S, Doan D N, Kim H K, Shang L, Loh T P, Hill J, and Vasudevan S G. 2011. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Antiviral Res, 92: 96-101.
102. Shi P Y, Tilgner M, and Lo M K. 2002. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology, 296: 219-233.
103. Shi P Y, Tilgner M, Lo M K, Kent K A, and Bernard K A. 2002. Infectious cDNA clone of the epidemic west nile virus from New York City. J Virol, 76: 5847-5856.
104. Shi P Y, Kauffman E B, Ren P, Felton A, Tai J H, Dupuis A P, 2nd, Jones S A, Ngo K A, Nicholas D C, Maffei J, Ebel G D, Bernard K A, and Kramer L D. 2001. High-throughput detection of West Nile virus RNA. J Clin Microbiol, 39: 1264-1271.
105. Shiryaev S, Ratnikov B, Chekanov A, Sikora S, Rozanov D, Godzik A, Wang J, Smith J, Huang Z, Lindberg I, Samuel M, Diamond M, and Strongin A. 2006. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J., 393: 503-511.
106. Sidique S, Shiryaev S A, Ratnikov B I, Herath A, Su Y, Strongin A Y, and Cosford N D. 2009. Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase. Bioorg Med Chem Lett, 19: 5773-5777.
107. Steuer C, Gege C, Fischl W, Heinonen K H, Bartenschlager R, and Klein C D. 2011. Synthesis and biological evaluation of alpha-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. Bioorg Med Chem, 19: 4067-4074.
108. Stoermer M J, Chappell K J, Liebscher S, Jensen C M, Gan C H, Gupta P K, Xu W J, Young P R, and Fairlie D P. 2008. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem, 51: 5714-5721.
109. Tan B H, Fu J, Sugrue R J, Yap E H, Chan Y C, and Tan Y H. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology, 216: 317-325.
110. Tassaneetrithep B, Burgess T H, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller M A, Pattanapanyasat K, Sarasombath S, Birx D L, Steinman R M, Schlesinger S, and Marovich M A. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med, 197: 823-829.
111. Tiew K C, Dou D, Teramoto T, Lai H, Alliston K R, Lushington G H, Padmanabhan R, and Groutas W C. 2012. Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives. Bioorg Med Chem, 20: 1213-1221.
112. Tomlinson S M, and Watowich S J. 2011. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Antiviral Res, 89: 127-135.
113. Tomlinson S M, and Watowich S J. 2012. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors. Antiviral Res, 93: 245-252.
114. Tomlinson S M, Malmstrom R D, Russo A, Mueller N, Pang Y P, and Watowich S J. 2009. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res, 82: 110-114.
115. Umareddy I, Chao A, Sampath A, Gu F, and Vasudevan S G. 2006. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen Virol, 87: 2605-2614.
116. USGS. 2010. Disease Maps 2010. http://diseasemaps.usgs.gov/.
117. Warrener P, Tamura J K, and Collett M S. 1993. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J Virol, 67: 989-996.
118. Wegzyn C M, and Wyles D L. 2012. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Curr Opin Pharmacol, 12: 556-561.
119. Wengler G. 1981. Terminal sequences of the genome and replicative-from RNA of the flavivirus West Nile virus: absence of poly(A) and possible role in RNA replication. Virology, 113: 544-555.
120. Wengler G. 1991. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology, 184: 707-715.
121. Westaway E G, Brinton M A, Gaidamovich S Y, Horzinek M C, Igarashi A, Kaariainen L, Lvov D K, Porterfield J S, Russell P K, and Trent D W. 1985. Flaviviridae. Intervirol., 24: 183-192.
122. WHO. 2009. Immunization, vaccines and biologicals: Japanese encephalitis. 〈 http://www.who.int/nuvi/je/en/ âŒ.
123. WHO. 2009. Dengue factsheet. 〈 http://www.who.int/ mediacentre/factsheets/fs117/en/ âŒ.
124. WHO. 2009. Yellow fever factsheet. 〈 http://www.who.int/mediacentre/factsheets/fs100/en/ âŒ.
125. Wyles D L. 2012. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med, 20: 139-145.
126. Wyles D L. 2013. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis, 207Suppl 1: S33-39.
127. Xu S, Li H, Shao X, Fan C, Ericksen B, Liu J, Chi C, and Wang C. 2012. Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease. J Med Chem, 55: 6881-6887.
128. Yang C C, Hsieh Y C, Lee S J, Wu S H, Liao C L, Tsao C H, Chao Y S, Chern J H, Wu C P, and Yueh A. 2011. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother, 55: 229-238.
129. Yin Z, Patel S J, Wang W L, Wang G, Chan W L, Rao K R, Alam J, Jeyaraj D A, Ngew X, Patel V, Beer D, Lim S P, Vasudevan S G, and Keller T H. 2006. Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead. Bioorg Med Chem Lett, 16: 36-39.
130. Yin Z, Patel S J, Wang W L, Chan W L, Ranga Rao K R, Wang G, Ngew X, Patel V, Beer D, Knox J E, Ma N L, Ehrhardt C, Lim S P, Vasudevan S G, and Keller T H. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett, 16: 40-43.
131. Zhang Y, Corver J, Chipman P R, Zhang W, Pletnev S V, Sedlak D, Baker T S, Strauss J H, Kuhn R J, and Rossmann M G. 2003. Structures of immature flavivirus particles. EMBO J., 22: 2604-2613.
132. Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, Guo Y, Bernard K A, Shi P Y, and Li H. 2007. Structure and function of flavivirus NS5 methyltransferase. J Virol, 81: 3891-3903.